J&J Win Blocking Mylan Schizophrenia Treatment Upheld on Appeal
Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit convinced a federal appeals court Mylan Laboratories Ltd.’s planned ...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
Zacks Investment Research on MSN1d
Silgan Holdings (SLGN) is a Top-Ranked Growth Stock: Should You Buy?
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Time to Sell Mylan; Two Better Picks
Mylan has been in the news for hiking prices on its EpiPen. The stock is flat since we recommended it in March, but we now ...